Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by MrMugsyon Dec 14, 2020 6:02pm
257 Views
Post# 32102884

Let's dream a little dream ... shall we ?

Let's dream a little dream ... shall we ?We have time to kill ... so lets !

The term is "thiol-mediated uptake" and the thought w.r.t. blocking viruses goes something like this:

The thiol-mediated uptake of organic molecules similar to alcohols, where oxygen is replaced by a sulphur atom, is one of the entry mechanisms, with its use by Human Immunodeficiency Virus (HIV) demonstrated a few years ago.Nov 23, 2020

Block viruses at the cell level using sulphur ?

I'm not suggesting that Antibe has an effective manner in which to do this.  I'm just saying that a tabled mention of ATE being in the "gaseous mediator" space and more so in the future, might have some interesting related opportunities ... but ... we can only guess at this point.  

Let's dream a little dream ... shall we?  hahaha

-------


"A research group from the University of Geneva (UNIGE) has identified inhibitors that are up to 5,000 times more effective than the one most often used today."

https://www.sciencedaily.com/releases/2020/11/201120113836.htm

I'm thinking ... if we can find the right molecule(s) and the right measurement techniques ... maybe we can advace such studies and drug development in gaseous mediators to be effective at the cell level. 

I know K-rap.  Please understand that.  Just dreaming a little dream my friends.


<< Previous
Bullboard Posts
Next >>